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PURPOSE: This study focused on circulating levels of vascular endothelial growth factor in patients with prostate cancer compared
to a normal population.
METHODS: We analyzed 26 normal individuals and 80 patients with prostate cancer. Blood was drawn from all subjects, and
plasma was extracted to determine the concentration of vascular endothelial growth factor using a quantitative immunoassay
technique (ELISA—enzyme-linked immunosorbent assay).
RESULTS: The median plasma level of vascular endothelial growth factor was significantly elevated in patients with metastatic
disease compared to patients with localized disease and with healthy controls. Patients with serum prostate-specific antigen > 20
ng/mL had significantly higher levels of plasma vascular endothelial growth factor than patients with serum prostate-specific
antigen < 20 ng/mL. There was a trend for patients with a Gleason score of 8 to 10 to have higher levels of plasma vascular
endothelial growth factor when compared to patients with lower Gleason scores. No relationship was found between plasma
vascular endothelial growth factor and clinical staging, or between plasma vascular endothelial growth factor and prostate volume,
in patients with localized prostate cancer.
CONCLUSION: This study indicates that patients with metastatic prostate cancer have higher plasma vascular endothelial
growth factor levels than patients with localized disease or in healthy controls.
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INTRODUCTION
The incidence of prostate cancer in Brazil is high. There
were 32,240 new cases and 8,230 deaths due to prostate
cancer in Brazil according to the most recent data from the
Instituto Nacional do Câncer (INCA) in 2003.1 Angiogen-
esis is defined as the development of new blood vessels for
tissue formation. The development of a vascular supply is
essential for organ formation and regeneration, tissue dif-
ferentiation during embriogenesis, wound healing, repro-
ductive functions in adults, and tumor tissue formation.2
Angiogenesis, important for tumor formation, can be meas-
ured using microvessel density and circulating levels of re-
lated growth factors such as vascular endothelial growth
factor (VEGF). Vascular endothelial growth factor plays an
important role in angiogenesis regulation, and its role in
human tumor formation is well established. The
overexpression of VEGF in human tumors is related to in-
creased vessel density and poor prognosis.2 Expression of
402
CLINICS 2006;61(5):401-8Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients
Duque JLF et al.
VEGF in normal prostate tissue was first described in 1995
by Brown et al.3 After this study, several groups reported
the expression of VEGF in prostatic tissues, demonstrat-
ing that VEGF is overexpressed in tumors and in poorly
differentiated tissues when compared to normal tissues,
proving the importance of VEGF in the pathogenesis of
prostate cancer.4-6
The measurement of circulating levels of VEGF was
initially described by Yamamoto et al,7 who reported that
serum VEGF levels were higher in cancer patients when
compared to normal individuals. Subsequently, other arti-
cles analyzing circulating levels of VEGF in many types
of cancer have been published.8 Serum levels of VEGF have
been correlated with stage of disease in colorectal cancer.
In patients with lung cancer, serum levels of VEGF have
been correlated with poor clinical outcome (survival and
treatment response). Patients with liver cancer, particularly
those with metastatic disease, had higher circulating VEGF
levels when compared to normal individuals. A strong cor-
relation between circulating VEGF levels and advanced or
metastatic breast cancer has been reported. There is con-
troversy among different studies analyzing circulating
VEGF levels in ovarian cancer.
Recently, several groups have reported that the analy-
sis of circulating VEGF levels in serum is problematic be-
cause VEGF is present in platelets and is released during
the clotting process. Consequently, the quantitative meas-
urement of VEGF by ELISA can be directly affected by
number of platelets present in the serum sample. Most
measurements of circulating VEGF levels in cancer patients
published in the literature have been of serum VEGF lev-
els. Banks et al claims that serum VEGF measurements are
“totally unsuitable” and recommended the use of citrate or
ethylenediaminetetraacetic acid (EDTA) plasma for VEGF
quantitation in blood.9
The purpose of this study was to quantify plasma VEGF
in patients with prostate cancer and in normal individuals,
and to correlate plasma VEGF levels with clinical stage,
serum PSA, histological grade, and prostate volume in pa-
tients with prostate cancer.
METHODS
Subjects
A total of 80 patients with prostate cancer (from a sin-
gle institution, diagnosed in 1998) and 26 cancer-free in-
dividuals (control group) were retrospectively analyzed.
Control subjects older than 50 years presented with a nor-
mal digital rectal examination and normal prostate-specific
antigen (PSA) levels (values between 0 and 4 ng/mL us-
ing the Hybritech® PSA test; Hybritech, Fullerton, CA). All
clinical information from the 80 patients with prostate can-
cer was extracted from clinical records. Fifty-four patients
were considered to have localized prostate cancer accord-
ing to clinical parameters (digital rectal examination, PSA,
and bone scan). Twenty-six patients were considered to
have metastatic disease according to a positive bone scan
or histologic confirmation of cancer metastasis to the pel-
vic lymph node after node dissection. Patients with meta-
static disease had not been hormonally manipulated before
blood withdrawal. For clinical classification of patients with
localized disease, the TNM classification system was
adopted (1997). The clinical classification of patients with
localized disease was performed by different urologists. We
grouped them into T1c, T2, and T3 groups to avoid data
dispersion. To analyze the correlation between VEGF and
PSA, a PSA value of 20 ng/mL was adopted as a cutoff,
since patients with PSA >20 ng/mL have a much higher
incidence of metastatic disease.10 For the analysis of his-
tological grade, we divided cancer patients into 3 groups:
patients with poorly differentiated tumors (Gleason score,
8, 9, and 10), patients with moderately differentiated tumors
(Gleason score, 7) and well differentiated tumors (Gleason
score, 5 and 6); because of their distinct behavior.11 Pros-
tate volume was estimated by transrectal ultrasound in 51
out of 54 patients with localized disease.
Vascular endothelial growth factor (VEGF)
measurements
Peripheral blood samples were drawn from the arm for
all subjects, placed immediately in sterile tubes contain-
ing 0.057 mL of 15% EDTA, taken immediately to the
laboratory for processing of plasma (centrifugation at 1000
x g), and stored in a liquid nitrogen freezer at -70°C. One
freeze-thaw cycle was used for all samples. The VEGF con-
centrations were determined using an ELISA method
(Quantikine, R&D Systems, Minneapolis, Minn), accord-
ing to the manufacturer’s protocol. Values were calculated
and converted to picograms per milliliter (pg/mL).
Statistical analysis
The Pearson correlation coefficient was calculated as a
measure of linear association between continuous variables,
including age, serum PSA, prostate volume, and plasma
VEGF. The Kolmogorov-Smirnov test revealed significant
departures from normality for plasma VEGF levels. Con-
sequently, median VEGF levels were compared among the
3 groups of patients (controls, localized disease, and meta-
static disease) using the nonparametric Kruskal-Wallis 1-
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way layout procedure, followed by the Mann-Whitney U
test. Vascular endothelial growth factor levels were also
compared among Gleason score and clinical stage sub-
groups with the same approach. A Bonferroni correction
was used to adjust the type 1 error rate for multiple com-
parisons, such that 2-tailed P < 0.017 was considered sig-
nificant. Data analysis was performed using Statistical
Analysis System version 6.12 statistical software.
RESULTS
Correlation between plasma VEGF levels and age
The median age of patients in the control group was
48.5 years (from 32 to 69 years), and 66 years in the pros-
tate cancer group (45 to 84 years). The median age of the
control group was significantly lower than the median age
of the cancer group (P < 0.05). However, we found no re-
lationship between age and plasma VEGF in patients with
localized disease, metastatic disease, or controls (r = 0.10;
P = 0.29) (Figure 1).
Comparison of plasma VEGF levels in patients with
localized disease, metastatic disease, and control group
The median levels of VEGF in the 3 groups (controls,
n = 26; localized disease, n = 54; and metastatic disease,
n = 26) were compared. The Kruskal-Wallis test showed
significant differences among the 3 groups (P < 0.001). The
Mann-Whitney U test reveled a significant difference be-
tween controls and patients with metastatic disease, and
between patients with localized and metastatic disease (P
<0.001 and P <0.003, respectively). Table 1 and Figure 2
show the distribution of VEGF values among the 3 groups.
Correlation between Gleason score and plasma VEGF
levels
The Gleason scores obtained from prostate needle bi-
opsy were analyzed for an association with plasma VEGF
levels. Six patients were excluded from the study because
of lack of data. One patient with Gleason 2 + 2 was ex-
cluded. Therefore, 73 patients were analyzed. There were
no differences in plasma VEGF levels among the groups
based on the Kruskal-Wallis test (P = 0.18). However, there
was a trend for VEGF to be higher among patients with
Gleason score 8 to 10 (Table 2).
Correlation between plasma VEGF levels and serum
PSA in patients with prostate cancer
We did not observe a linear correlation between serum
PSA and plasma VEGF levels (r = 0.14; P = 0.22). How-
ever, patients with PSA levels greater than 20 ng/mL had
Table 1 - Plasma vascular endothelial growth factor (VEGF)
concentrations in the 3 groups analyzed
Group n Median VEGF Mean VEGF
(pg/mL) (pg/mL)
Controls 26 0 (0-24)* 12.7
Localized disease 54 7.0 (0-26.5) 26.7
Metastatic disease 26 28.5 (19.3-57) 41.9
P < 0.001; *Number in parentheses = interquartile range
Figure 1 - Relationship between age and plasma vascular endothelial growth
factor (VEGF).
Figure 2 - Median plasma vascular endothelial growth factor (VEGF)
concentrations in control, localized disease, and metastatic disease groups.
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significantly higher plasma VEGF values than patients with
PSA levels less than 20 ng/mL (Table 3). Two patients were
excluded for not having PSA levels determined at the time
of the analysis.
Correlation between clinical stage and plasma VEGF
in patients with localized disease
Regarding the 54 patients with localized prostate can-
cer, VEGF levels were not related to clinical stage (P =
0.54). Six patients were excluded from the analysis for not
having clinical stage described in the clinical records. Ta-
ble 4 shows plasma VEGF levels according to clinical stage.
Correlation between prostate volume and plasma
VEGF levels in patients with localized prostate cancer
No correlation between plasma VEGF levels and pros-
tate volume in patients with localized disease were found
(Table 5). Three patients were excluded from the analysis
because they did not have measurements of prostate vol-
ume when transrectal ultrasound was performed.
DISCUSSION
Angiogenesis, essential for tumor formation and the
object of intense research, can be measured by microvessel
density and by measurement of circulating levels of related
growth factors, such as VEGF. Several studies suggest that
the measurement of circulating levels of VEGF is a useful
tool for analyzing prognosis and clinical outcome in many
tumors. In the present study, plasma levels of VEGF was
correlated with several parameters related to prostate can-
cer, such as age, serum PSA, histological grade, clinical
stage, and prostate volume.
No correlation was found between plasma VEGF and
age of the patients. In the selection of the control group a
younger population sample was deliberately collected in
order to avoid inclusion of patients with occult prostate can-
cer in this group. Accordingly, Yamamoto et al analyzed
184 normal individuals with ages varying from 21 to 59
years and found no correlation between age and circulat-
ing VEGF levels.7 Kumar et al also found no correlation
between VEGF levels and age in a population of 136 indi-
viduals with ages varying from 20 to 80 years.12
In this study, plasma VEGF levels were significantly
higher in patients with metastatic prostate cancer in com-
parison to patients with localized disease and healthy con-
trols (P <0.001, Table 1). These findings are consistent with
the study of Salven et al, which found elevated VEGF lev-
els in patients with metastatic disease, although the fluid
analyzed was serum in that study.13
Reported data regarding the measurement of circulat-
ing VEGF levels in patients with prostate cancer is scarce.
Jones et al measured VEGF in the serum of 78 individuals
(21 controls, 9 with benign prostate hyperplasia, 16 with
localized prostate cancer, and 32 with metastatic prostate
cancer) and found elevated VEGF levels only in patients
with hormonal-refractory metastatic prostate cancer. 14 They
found no differences in serum VEGF levels among controls,
localized disease, and metastatic disease. They did not
analyze VEGF levels in regard to clinical stage, Gleason
score, or prostate volume. Their control group was also
composed of younger individuals. In our study, patients
Table 4 - Plasma vascular endothelial growth factor (VEGF)
levels according to clinical stage
Stage n Median VEGF Mean VEGF
(pg/mL) (pg/mL)
T1c 24 4.0 (0-18.8)* 24.4
T2 19 8.5 (4.7-20.5) 24.6
T3 5 4.5 (0-40) 16.9
P = 0.54; * interquartile range
Table 3 - Relationship between plasma vascular endothelial
growth factor (VEGF) and prostate-specific antigen (PSA)
PSA n Median VEGF Mean VEGF
(pg/mL) (pg/mL)
PSA > 20 ng/mL 22 44.5 (44.5-68.5)* 53.9
PSA < 20 ng/mL 56 5.5 (5.5-21.5) 20.1
P < 0.001; * interquartile range
Table 2 - Relationship between plasma vascular endothelial
growth factor (VEGF) and Gleason score
Gleason score n Median VEGF Mean VEGF
(pg/mL) (pg/mL)
5-6 29 5.5 (0.25-23)* 25.6
7 25 11.5 (0-35) 26.8
8-10 19 23.5 (8.5-47.5) 34.8
P = 0.18; * interquartile range
Table 5 - Plasma vascular endothelial growth factor (VEGF)
according to prostate volume
Vol. n Median VEGF Mean VEGF
(pg/mL) (pg/mL)
< 20 10 8.5 (1.5-19)* 15.0
20-40 29 13.5 (2.5-58.5) 39.5
> 40 12 2.5 (0-7.5) 13.4
P = 0.18; Vol. = prostate volume in cm3 ; * interquartile range
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with metastatic disease were not subdivided into hormone-
refractory and hormone-sensitive groups. Therefore, the
data cannot be compared with regard to this issue. Addi-
tionally, the 2 studies were not comparable because the
fluid analyzed was different (plasma vs serum). Several
studies in the literature analyzing circulating VEGF levels
in patients with cancer, report high levels of this molecule
in patients with advanced or metastatic cancer. 7,13 Such data
are compatible with both the study of Jones et al and our
study. The fact that Jones et al14 did not find differences
between patients with localized and metastatic disease may
reflect the small sample of their study (16 patients with lo-
calized and 23 patients with metastatic disease).
Another study with 197 patients with hormone-refrac-
tory prostate cancer reported plasma VEGF levels before
and after treatment with suramin (patients in the protocol
had already received hormones), and found an inverse cor-
relation between plasma VEGF and survival. Yet, using a
cutoff of 260 pg/mL, the plasma VEGF level was the
strongest predictor of survival in a multivariate analysis,
including other predictors such as serum PSA and alkaline
phosphatase.15 The data suggests that plasma VEGF may
be clinically relevant in patients with hormone-refractory
prostate cancer in terms of prognosis. However, plasma
VEGF may be more than a disease marker, also reflecting
a specific phenotype of a cancer that produces VEGF. Pro-
spective studies including tumor histological analysis
should be conducted to clarify this hypothesis.
Recently, Kohli et al reported a prospective study com-
paring two groups of patients with advanced prostate can-
cer in order to determine whether there is correlation be-
tween plasma VEGF and tumor progression (from hor-
mone-sensitive to hormone-refractory).16 The first group was
composed of patients with stable PSA during hormonal
treatment, and the second group had patients with progres-
sive PSA levels during treatment. There was no difference
between the two groups in regard to plasma VEGF levels.
One could argue that the development of metastatic spots
would depend on angiogenesis and, therefore, would be
accompanied by higher levels of related growth factors (like
VEGF) in patients with disease progression. Alternatively,
the increase in serum PSA levels in patients with disease
progression may exert an anti-angiogenic effect, lowering
circulating VEGF. The PSA anti-angiogenic effect on
VEGF occurs due to its proteolytic action on plasminogen,
creating an angiostatin-like protein with an anti-angiogenic
effect.
In this study, we found not only a relationship between
VEGF and advanced disease, but also a relationship be-
tween VEGF and other clinical parameters associated with
prostate cancer (PSA, clinical stage, and Gleason grade).
Patients with metastatic disease had significantly higher
VEGF levels than patients with localized disease and con-
trols. Although we did not find significant differences be-
tween the control group and patients with localized disease,
we observed a tendency of patients with localized disease
to have higher VEGF levels than controls. The lack of sta-
tistical significance could be attributed to the small sam-
ple size; a larger series may or may not confirm this hy-
pothesis. Yet, some patients with localized disease in this
study had high VEGF levels. The reason for elevated
plasma VEGF levels in patients with localized disease is
unknown. Prospective study and long term follow-up of
these patients should reveal whether patients with high
plasma VEGF levels present worse prognoses than patients
with low plasma VEGF levels. Even some patients in the
control group were found to have high plasma VEGF, for
unknown reasons. We should be aware that circulating
VEGF may be elevated in patients with other, noncancerous
disease.
We found no relationship between plasma VEGF and
clinical stage in patients with localized disease. Two issues
should be noted, ie, the limited sample size and the fact
that different urologists performed the digital rectal exami-
nation and clinical staging.
There was no relationship between plasma VEGF lev-
els and Gleason score; however, we observed a tendency
of patients with high Gleason scores (8 to 10) to have
higher VEGF levels than patients with low Gleason score
(5-6 or 7). Prostate cancer patients with high serum PSA
levels and high Gleason scores are more likely to have
metastatic disease.
No linear correlation between plasma VEGF and serum
PSA levels were observed. However, patients with PSA lev-
els greater than 20 ng/mL had significantly higher VEGF
values than patients with PSA levels less than 20 ng/mL.
This suggests that plasma VEGF is elevated in patients with
disseminated disease. When prostate cancer presents as an
organ-confined disease, plasma VEGF levels may not be
elevated, regardless of clinical stage, Gleason grade, and
PSA values.
In our study, there was no correlation between prostate
volume and VEGF levels in patients with localized disease.
Kohli et al, analyzing patients with localized prostate can-
cer, found no differences between patients who had under-
gone radical prostatectomy and patients with the intact
gland (before treatment) with regard to plasma VEGF lev-
els; this suggests that the prostate gland does not influence
VEGF levels.16 Although the results of both studies are the
same, the data are not comparable, because the respective
populations are totally different.
The results of our study suggest that plasma VEGF is
406
CLINICS 2006;61(5):401-8Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients
Duque JLF et al.
not affected by prostate size. However, George et al com-
pared plasma VEGF levels in patients before and after radi-
cal prostatectomy, and found a significant decrease in
VEGF levels after surgery, suggesting that the prostate
gland may be an important source of circulating VEGF.17
Additionally in this study, there was no correlation be-
tween plasma VEGF and other prognostic factors related
to prostate cancer before radical prostatectomy (PSA, clini-
cal stage, Gleason grade). However, Shariat et al measured
plasma VEGF in 215 patients with localized prostate can-
cer before radical prostatectomy and found a correlation
between plasma VEGF and prostate volume, Gleason grade
obtained from prostate needle biopsy and definitive surgery,
extra-prostatic disease, positive lymph nodes, and bio-
chemical failure after surgery.18 The control group also had
lower VEGF values than patients with localized prostate
cancer. Nine patients with metastatic disease had higher
VEGF values when compared to the group of 215 patients
with localized disease.
Based on all available published papers, controversies
and unanswered questions persist about the role of circu-
lating VEGF in prostate cancer patients. The role of VEGF
remains unknown, in part due to its low specificity. Pro-
spective studies with long-term follow-up may determine
whether circulating VEGF can be used as a prognostic
marker in patients with localized and metastatic disease,
or as a tool in selecting patients who will benefit from cura-
tive treatment. The value of VEGF in predicting lymph
node disease remains uncertain. Yet, VEGF can be tested
as a marker of response to treatment in patients with meta-
static prostate cancer.
CONCLUSION
This study indicates that patients with metastatic pros-
tate cancer have significantly higher plasma VEGF levels
than patients with localized disease or healthy controls.
RESUMO
Duque JLF, Loughlin KR, Adam RM, Kantoff P, Mazzucchi
E, Freeman MR. Medida da concentração plasmática do
fator de crescimento do endotélio vascular em pacientes
com câncer prostático: relação com estado clinico, gleason
score, volume prostático e PSA sérico. CLINICS.
2006;61(5): 401-8.
OBJETIVO: Analisar os níveis circulantes do fator de cres-
cimento do endotélio vascular em pacientes com câncer
prostático comparados com uma população de indivíduos
eutróficos.
MÉTODOS: Vinte e seis indivíduos eutróficos e oitenta
pacientes com câncer de próstata foram analisados nesse
estudo. A coleta sangüínea foi realizada da mesma manei-
ra em todos os pacientes e o plasma foi extraído para a
determinação dos níveis do fator de crescimento do
endotélio vascular, utilizando-se o método quantitativo
ELISA (enzyme-linked immunosorbent assay).
RESULTADOS: Os níveis de fator de crescimento do
endotélio vascular plasmático encontraram-se significati-
vamente elevados nos pacientes com doença metastática
quando comparados com pacientes com doença localizada
e com indivíduos sadios. Pacientes com PSA sérico maior
que 20 ng/ml apresentaram níveis maiores de fator de cres-
cimento do endotélio vascular plasmático quando compa-
rados com pacientes com PSA menor que 20 ng/ml. Hou-
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ve uma tendência dos pacientes com escore de Gleason de
8 a 10 apresentarem níveis maiores do fator de crescimen-
to do endotélio vascular plasmático em relação a pacien-
tes com escores de Gleason menores que 8. Não houve re-
lação entre fator de crescimento do endotélio vascular
plasmático e estado clínico, ou entre fator de crescimento
do endotélio vascular e volume prostático em pacientes com
câncer de próstata localizado.
CONCLUSÃO: Os dados indicam que pacientes com cân-
cer de próstata metastático apresentam níveis significati-
vamente mais elevados de fator de crescimento do endotélio
vascular plasmático quando comparados com pacientes
com câncer localizado e com indivíduos normais.
UNITERMOS: Câncer. Próstata. Fator de crescimento.
Metástases. Citocina.
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